Cargando…

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with congenital heart disease after Fontan‐procedure. Physiologically‐b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willmann, Stefan, Coboeken, Katrin, Zhang, Yang, Mayer, Hannah, Ince, Ibrahim, Mesic, Emir, Thelen, Kirstin, Kubitza, Dagmar, Lensing, Anthonie W. A., Yang, Haitao, Zhu, Peijuan, Mück, Wolfgang, Drenth, Henk‐Jan, Lippert, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520753/ https://www.ncbi.nlm.nih.gov/pubmed/34292671 http://dx.doi.org/10.1002/psp4.12688

Ejemplares similares

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
por: Willmann, Stefan, et al.
Publicado: (2013)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
por: Kubitza, Dagmar, et al.
Publicado: (2018)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
por: Willmann, Stefan, et al.
Publicado: (2022)

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects
por: Kubitza, Dagmar, et al.
Publicado: (2014)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
por: Schlender, Jan-Frederik, et al.
Publicado: (2018)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children
por: Ince, Ibrahim, et al.
Publicado: (2021)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
por: Lensing, Anthonie W. A., et al.
Publicado: (2018)

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study
por: Zhu, Peijuan, et al.
Publicado: (2022)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020)

Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
por: Palumbo, Joseph S., et al.
Publicado: (2022)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Ngo, Lien Thi, et al.
Publicado: (2020)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
por: Burghaus, Rolf, et al.
Publicado: (2011)

Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
por: Bratsos, Sosipatros
Publicado: (2019)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
por: Burghaus, Rolf, et al.
Publicado: (2014)

Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review
por: Alalawneh, Majdoleen, et al.
Publicado: (2022)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs
por: Meng, Yuanyuan, et al.
Publicado: (2022)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
por: Snelder, Nelleke, et al.
Publicado: (2019)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
por: Liu, Xiao-Qin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u4irh20b72du16i1ohn3aa7s7l